Comparative Pharmacology
Head-to-head clinical analysis: DEPODUR versus DURAGESIC 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPODUR versus DURAGESIC 75.
DEPODUR vs DURAGESIC-75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine sulfate extended-release liposomal injection; morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The analgesic effects are mediated by activation of mu-opioid receptors in the central nervous system, leading to modulation of pain pathways.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Epidural: 5-15 mg as a single dose (morphine sulfate 10 mg/mL extended-release liposome injection).
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
None Documented
None Documented
The terminal elimination half-life of morphine is approximately 2-4 hours in adults. However, DEPODUR (extended-release liposomal morphine) has a prolonged half-life due to slow release from the liposomal depot, with an effective half-life of about 12-24 hours, supporting once-daily dosing.
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Morphine is primarily excreted renally, with approximately 90% of the dose eliminated in urine within 24 hours, mainly as morphine-3-glucuronide (M3G, ~50%), morphine-6-glucuronide (M6G, ~10%), and unchanged morphine (~10%). Fecal excretion accounts for less than 10%.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic